Disease response to DLI
. | MRD . | Persistent disease . | Progression or relapse . |
|---|---|---|---|
| No. patients receiving DLI | 3 | 1 | 17 |
| Histology, no. | |||
| HG-NHL | 0 | 1 | 8 |
| MCL | 0 | 0 | 2 |
| LG-NHL | 3 | 0 | 7 |
| Donor source, no. | |||
| Sibling | 3 | 1 | 15 |
| MUD | 0 | 0 | 2 |
| Maximum dose, T cells/kg (range) | 5 × 107 (3-5 × 107) | 6 × 107 (—) | 108 (106-108) |
| No. doses, median (range) | 4 (3-5) | 3 (—) | 2 (1-4) |
| Response, no. | |||
| PR or CR | |||
| Transient | |||
| HG | 0 | 1 | 2 |
| MCL | 0 | 0 | 1 |
| LG | 2 | 0 | 4 |
| None | |||
| HG | 0 | — | 5 |
| MCL | 0 | — | 1 |
| LG | 1 | — | 2 |
| Not evaluable | |||
| HG | — | — | 1 |
| MCL | — | — | 0 |
| LG | — | — | 1 |
. | MRD . | Persistent disease . | Progression or relapse . |
|---|---|---|---|
| No. patients receiving DLI | 3 | 1 | 17 |
| Histology, no. | |||
| HG-NHL | 0 | 1 | 8 |
| MCL | 0 | 0 | 2 |
| LG-NHL | 3 | 0 | 7 |
| Donor source, no. | |||
| Sibling | 3 | 1 | 15 |
| MUD | 0 | 0 | 2 |
| Maximum dose, T cells/kg (range) | 5 × 107 (3-5 × 107) | 6 × 107 (—) | 108 (106-108) |
| No. doses, median (range) | 4 (3-5) | 3 (—) | 2 (1-4) |
| Response, no. | |||
| PR or CR | |||
| Transient | |||
| HG | 0 | 1 | 2 |
| MCL | 0 | 0 | 1 |
| LG | 2 | 0 | 4 |
| None | |||
| HG | 0 | — | 5 |
| MCL | 0 | — | 1 |
| LG | 1 | — | 2 |
| Not evaluable | |||
| HG | — | — | 1 |
| MCL | — | — | 0 |
| LG | — | — | 1 |
— indicates not applicable.